New second-generation TPO-RAs recently approved by the EMA, lusutrombopag and avatrombopag, provide an alternative solution to platelet transfusions for TCP management associated with CLD [36]. This evidence concerns the gene TPO and congenital secretory chloride diarrhea 1.